ROP16-Mediated Activation of STAT6 Suppresses Host Cell Reactive Oxygen Species Production, Facilitating Type III Toxoplasma gondii Growth and Survival

Toxoplasma gondii is an obligate intracellular parasite that infects up to one-third of the world’s population. Control of the parasite is largely accomplished by IFN-γ-dependent mechanisms that stimulate innate and adaptive immune responses.

Historically, T. gondii strains were originally characterized into three clonal lineages (types I, II, and III) based on their acute virulence phenotype in mice (3,14). Type I strains are highly virulent in laboratory mice, while type II strains exhibit an intermediate virulence, and type III strains are considered avirulent (14). Of the canonical strains, types I and III are more genetically similar compared to type II. Advances in sequencing capabilities have led to T. gondii strains now falling into 15 genetic haplotypes of which type I, type II, and type III are now called haplotypes 1, 2, and 3 and clades A, D, and C, respectively (14,15). Our knowledge of how type I, II, and III strains cause distinct acute disease outcomes in mice has been mapped to differences in the proteins that the parasite secretes into its host cell during and after the invasion process (16)(17)(18). These studies also identified several polymorphic proteins that seemed to have no role in lethality of type I strains in mice (19)(20)(21). One possibility for the role of these polymorphic proteins is that these strain-specific differences are critical to parasite survival in different, yet-to-be-identified hosts (16). Another possibility is that some of these proteins do not influence disease outcomes of the hypervirulent type I strains but may be critical in the less virulent strains.
One such polymorphic effector protein is rhoptry protein 16 (ROP16). ROP16s from types I, II, and III translocate into the host cell nucleus and have a functional kinase domain, but only the type I and III alleles, which are 99% identical in their amino acid sequence, cause prolonged phosphorylation and activation of STAT3 and 6 and potentially STAT5a (21)(22)(23)(24). A single amino acid change in the type II allele of ROP16 renders it incapable of STAT activation (24). In macrophages, the ability of the type I allele of ROP16 to cause prolonged activation of STAT3/6 leads to decreased production of IL-12, a key proinflammatory cytokine involved in generating the IFN-g response (21,22). In the context of highly virulent type I strains, ROP16 has only a minimal effect on pathogenesis in mice (21), but ROP16's role in avirulent type III strains has been understudied.
Our group and another recently demonstrated that ROP16 plays a key role in determining the acute and central nervous system (CNS) immune response in mice and is required for efficient type III parasite persistence in mice, possibly by regulating the early immune response (25,26). During that work, we also identified an IFN-g-independent in vitro growth defect in human fibroblasts in a type III strain that lacked ROP16 (IIIDrop16). Given this IFN-g-independent phenotype, we hypothesized that different mechanisms accounted for the in vivo and in vitro survival defects of the IIIDrop16 strain. Here, we expand on those initial findings by complementing the IIIDrop16 parasites with a series of ROP16 mutants that lack different ROP16 domains/ functions. These experiments determined that efficient in vitro growth required a functional kinase domain and the ability to phosphorylate STATs. Consistent with these data, the activation of STAT3/6 via cytokine stimulation was sufficient to restore parasite growth in IIIDrop16 parasites. Given the recent finding that type III strains are killed in naive murine macrophages in a reactive oxygen species (ROS)-dependent manner (27), we sought to determine if ROP16 was influencing host cell ROS production in human cells. Indeed, we found that host cells infected with IIIDrop16 parasites accumulated ROS and that pharmacological inhibition of NADPH oxidase 2 (NOX2) and mitochondrially derived ROS restored IIIDrop16 parasites growth to wild-type levels. Finally, using short hairpin RNA (shRNA) knockdown cells and mouse ear tip fibroblasts (mETFs) derived from STAT6 knockout (STAT6KO) mice, we determined that activation of STAT6 was needed for suppression of host cell ROS production and efficient parasite growth and survival. These findings highlight a mechanism by which type III T. gondii strains evade IFN-g-independent cell-autonomous defenses in human and murine cells. IIIDrop16 strain showed an in vitro IFN-g-independent growth defect, while the in vivo deficit related to murine IFN-g-dependent mechanisms, suggesting that ROP16 might enhance type III parasite fitness in multiple ways (25,26). To better define this in vitro growth defect, we sought to identify which functional domains of ROP16 were required for efficient parasite growth. To accomplish this goal, we generated a series of IIIDrop16 complemented strains, which expressed the type II ROP16 (ROP16 II ), type III ROP16 (ROP16 III ), or domain mutants that were catalytically inactive (ROP16 IIIKD ) or lacked a nuclear localization sequence (ROP16 IIIDNLS ) (Fig. 1B). Finally, as previous work had demonstrated that a single polymorphic amino acid on ROP16 determined the strain-specific activation of STAT3 and was predicted to determine the activation of STAT5a and 6, we also generated complemented strains that expressed a ROP16 III in which the leucine at position 503 was switched to a serine, rendering it "STAT-dead" (ROP16 IIISD ), or expressed a ROP16 II in which the serine at position 503 was changed to a leucine, rendering it "STAT-active" (ROP16 IISA ) (Fig. 1B) (24). We validated the deletion and reintroduction of rop16 in our transgenic strains using a locus-specific PCR that amplifies a 1,000-bp product in the coding sequence of rop16 (see Fig. S1A in the supplemental material). We confirmed expression of our ROP16 constructs via immunofluorescent (IFA) staining of their engineered FLAG tag ( Fig. S1A and B). Finally, we confirmed that our ROP16 IIIDNLS -expressing strain was unable to translocate to the nucleus of the host cell (Fig. S1C).
As most work has been done with the type I ROP16 allele, we first sought to confirm that the type III allele also causes prolonged activation of STAT3, 5a, and 6. To that end, we analyzed human foreskin fibroblasts (HFFs) infected with our panel of engineered type III strains (Fig. 1B). As expected, given that the type III allele is 99% identical at the amino acid level (3 to 6 amino acid differences) to the type I allele, wild-type (WT III ) and ROP16 III parasites induced prolonged phosphorylation of STAT3, 5a, and 6 while the IIIDrop16, ROP16 II , and ROP16 IIIKD strains did not ( Fig. 1C and D). Additionally, we found that the single polymorphic amino acid in ROP16 that determines the strainspecific activation of STAT3 also determines activation of STAT5a and STAT6 ( Fig. 1C and D). Consistent with prior studies, the lack of an NLS had no effect on STAT3 and 6 phosphorylation but significantly decreased STAT5a phosphorylation ( Fig. 1C and D).
Together, these data show that the type III allele of rop16 is a functional kinase capable of activating STAT3, 5a, and 6. Additionally, the leucine at position 503 dictates the ability of ROP16 to activate not only STAT3 but also STAT5a and STAT6. Finally, mutation of the NLS in ROP16 leads to decreased phosphorylation of STAT5a, but not STAT3 or STAT6.
ROP16 facilitates parasite growth and survival. We previously reported that IIIDrop16 parasites were defective in plaque production in vitro, but not in invasion and attachment, indicating a possible defect in parasite growth and survival (25). To further characterize this defect, we performed a plaque assay using our newly generated panel of ROP16 parasites. IIIDrop16, ROP16 II , ROP16 IIISD , and ROP16 IIIKD parasites were all defective in forming plaques compared to WT III parasites. ROP16 III , ROP16 IISA , and ROP16 IIIDNLS parasites formed plaques at levels comparable to WT III ( Fig. 2A).
To test whether this defect in plaque formation was at the level of parasite growth, we infected confluent monolayers of HFFs with our parasite strains and then enumerated the number of parasites per parasitophorous vacuole (PV) at 24 h postinfection (hpi). We found that the ROP16 II , ROP16 IIISD , and ROP16 IIIKD strains displayed an accumulation of PVs that contained only one parasite compared to WT III parasites,   indicating an overall growth defect, while parasites expressing ROP16 III , ROP16 IISA , or ROP16 IIIDNLS had WT III levels of growth (Fig. 2B).
As a recent study demonstrated that type III strains are cleared from naive murine bone marrow-derived macrophages (BMDMs) without the need for IFN-g stimulation (27), we decided to test if our ROP16 strains were being cleared in HFFs. To this end, we infected confluent monolayers of HFFs with our parasites and then fixed and counted the number of infected cells every 6 h for 24 h. We observed a steady accumulation of the percentage of infected cells over 24 h in our WT III , ROP16 III , and ROP16 IISA strains but noticed a significant decrease in the number of infected host cells in our ROP16 II , ROP16 IIISD , and ROP16 IIIKD strains (;15 to 20% on average) over time, indicating that parasites were being cleared in an IFN-g-independent manner (Fig. 2C). The ROP16 IIIDNLS strain showed a significant but less pronounced clearance in HFFs (Fig. 2C).
Together, these data indicate that ROP16 is needed for efficient parasite growth and survival in vitro. Efficient parasite growth and survival in vitro are dependent on kinase activity, and the ability of ROP16 IISA to restore these defects suggests that activation of STATs is necessary as well. Interestingly, while the ROP16 IIIDNLS -expressing strain had no growth defect, there was a small but significant increase in parasite clearance, indicating that nuclear localization of ROP16 may play a limited role in parasite survival. Finally, we expanded on recent work (25)(26)(27) by showing that ROP16 suppresses clearance of type III parasites in unstimulated human fibroblasts.
Type III parasites accumulate ROS in their host cells in a ROP16-dependent manner. IFN-g exerts its antiparasitic effects at the cellular level by upregulating immunity-related GTPases (IRGs) and guanylate binding proteins (GBPs) that disrupt the PV and lead to eventual clearance of the parasite in mice (28)(29)(30)(31)(32)(33)(34). Several other studies have also implicated the IFN-g-dependent production of nitric oxide and autophagyrelated clearance (21,35,36). Given that human cells lack the same IRG systems and our observation of an IFN-g-independent defect in parasite growth and survival, we reasoned that the mechanism of parasite suppression and clearance in vitro must be something other than these canonically described IFN-g-dependent mechanisms.
Prior work demonstrated that host cells infected with type I parasites deficient in ROP16 showed an accumulation of reactive nitrogen species (RNS) in an IFN-g-dependent manner (21). Given that the type III strain has shown significant differences from the type I strain (25,26), we sought to determine if IFN-g-independent RNS production might also be playing a role in the IIIDrop16 survival defect by quantifying RNS levels in host cells. We observed no difference in RNS accumulation among any of our strains in our unstimulated HFFs, indicating that IFN-g-independent RNS production is not playing a role in the ROP16-dependent clearance we see in HFFs ( Fig. S2A).
As a recent study demonstrated that type III parasites are cleared by ROS-dependent and GBP5-dependent mechanisms in naive murine BMDMs (27), we hypothesized that these mechanisms might be involved in the restriction and clearance of IIIDrop16 parasites in HFFs. To test whether GBP5 was involved, we infected confluent monolayers of HFFs, treated with or without IFN-g, with our parasite strains and quantified the accumulation of GBP5 around parasite-containing vacuoles. At 9 hpi, we detected little GBP5 accumulation around the PV (1 to 3%) regardless of ROP16 status in untreated HFFs (Fig. S2B). Prestimulation with IFN-g resulted in an increase in GBP5 accumulation around PVs, but ROP16 status did not affect GBP5 localization to the PV (Fig. S2B).  Finally, to test whether ROS played a role in parasite restriction, we infected confluent monolayers of HFFs with our parasite strains, and at 18 hpi, we quantified host cell ROS accumulation via IFA. In cells infected with the IIIDrop16, ROP16 II , ROP16 IIISD , and ROP16 IIIKD strains, we observed an increased accumulation of ROS compared to cells infected with WT III parasites (Fig. 3A). Though not statistically significant (P value = 0.3163, 0.3505, 0.2217, and 0.7847, respectively), the uninfected cells in these cultures showed a trend toward an increased accumulation of ROS compared to uninfected cells in cultures with WT III parasites. In ROP16 III -, ROP16 IISA -, and ROP16 IIIDNLS -infected cultures, infected and uninfected host cells displayed similar levels of ROS accumulation as WT III -infected cultures (Fig. 3A).
Given the accumulation of host cell ROS, but not RNS or GBP5, in cultures infected with IIIDrop16 parasites, we hypothesized that ROS was the major driver of the growth and survival defects in our IIIDrop16 strain. To test this hypothesis, we pharmacologically inhibited ROS production using a ROS inhibitor, N-acetyl-L-cysteine (NAC), during infection and then quantified parasite growth and survival. Consistent with ROS driving the IIIDrop16 defects, treatment of HFFs with NAC for 6 or 24 h was sufficient to restore growth of IIIDrop16 parasites to WT III levels (Fig. 3B). However, only 24-h treatment of NAC was sufficient to restore survival of IIIDrop16 parasites (Fig. 3C). NAC treatment during IIIDrop16 infection was also sufficient to reduce ROS to levels comparable to HFFs infected with WT III (Fig. S3). Taken together, these data demonstrate that ROP16dependent suppression of ROS accumulation is a key mechanism used by type III parasites to avoid clearance by host cells.
ROS-mediated clearance of IIIDrop16 also occurs in murine macrophage-like cell lines. We next sought to determine if ROP16-mediated ROS accumulation restricted parasites in mouse and human macrophage cell lines. We infected either IC-21s, a mouse macrophage-like cell line (37), or THP1s, a human monocyte cell line (38) that converts to macrophages when treated with 12-O-tetra-decanoylphorbol-13-acetate (TPA) (39), with WT III , IIIDrop16, or ROP16 III parasites and measured parasite growth and survival. Similar to our results in HFFs, IIIDrop16 parasites exhibited a growth defect compared to WT III parasites that could be restored with a 24-h treatment of NAC in both cell lines (Fig. 4A). While infection of IC-21s with WT III , IIIDrop16, or ROP16 III resulted in a decrease in parasite survival, only IIIDrop16 exhibited an increased clearance in this cell type compared to WT III , and this increased clearance could be inhibited by treatment with NAC (Fig. 4B). Interestingly, despite IIIDrop16 exhibiting a growth defect in differentiated THP1s, there was no effect on parasite survival for any of the indicated strains (Fig. 4B). Finally, we quantified ROS accumulation in these cell lines during infection. In keeping with previous results, IC-21s infected with IIIDrop16 parasites had an increased amount of ROS compared to WT III , while differentiated THP1s infected with IIIDrop16 did not (Fig. 4C). Together, these results indicate that ROP16dependent suppression of ROS accumulation occurs in murine macrophage-like cells but not in human macrophages differentiated from a monocyte cell line, suggesting that ROP16 effects may vary between hosts and cell types.
Suppression of STAT6 results in accumulation of ROS and a defect in type III parasite growth and survival. Given the ability of ROP16 IISA but not ROP16 IIISD to restore parasite growth and survival, our data suggested, but did not directly show, that STAT activation was involved in suppressing host cell ROS production. To determine if STAT activation was needed for parasite growth and survival, we prestimulated HFFs with either IL-4 or IL-6 (40)(41)(42)(43)(44). Prestimulation of HFFs with either IL-4 or IL-6 resulted in the activation of STAT3 and 6, but not STAT5a (Fig. S4A). Additionally, IL-4 or IL-6 prestimulation of HFFs fully restored growth of IIIDrop16 to WT III levels but only partially restored parasite survival ( Fig. S4B and C). Together, these data indicate that STAT3 and 6 may be required for type III parasite growth and survival, while STAT5a may play a less prominent role.
To determine which STAT was involved in ROS production, we generated STAT3, STAT5a, and STAT6 knockdown HFF cell lines. We transduced HFFs with lentiviral vectors encoding shRNAs targeting STAT3, STAT5a, or STAT6 and then isolated single cells  to establish clonal cell lines. We used Western blot analysis to determine knockdown efficiency and verify that only the targeted STAT was affected. We achieved knockdown efficiency of up to 60 to 80% of the targeted STAT (Fig. S5). We then tested growth and survival of WT III parasites in these cell lines. Only the STAT6 knockdown cell line showed a growth and survival defect comparable to previous results with IIIDrop16 ( Fig. 5A and B). Interestingly, the STAT3 knockdown cells displayed a strong defect in parasite survival but not parasite growth (Fig. 5A and B). This finding is consistent with a recent report demonstrating that early ROP16-independent activation of STAT3 during the invasion process of host cells prevents parasite targeting by autophagy (45). As this finding is ROP16 independent and does not explain the growth defect found in our IIIDrop16 strains, we reasoned that lack of STAT6 activation was more likely to explain the ROS-mediated killing effect in HFFs.
To test whether STAT6 suppression results in ROS accumulation during infection, we infected our knockdown cell lines with WT III parasites and quantified host cell ROS levels. We observed the accumulation of ROS specifically in the STAT6 knockdown cells but not in the STAT3 or STAT5a knockdown cell lines (Fig. 5C). To determine if STAT6mediated ROS accumulation also played a role in mouse cells, we generated mETFs from STAT6KO mice and infected them with WT III parasites. Deletion of STAT6 from mETFs resulted in a defect in parasite growth and survival and an accumulation of ROS in infected host cells (Fig. 5D to F). Together, these data indicate that activation of STAT6 is required for suppression of host cell ROS production, which enables efficient type III parasite growth and survival in both human and mouse fibroblasts.
Pharmacological suppression of NOX2-and mitochondrially derived ROS is sufficient to restore parasite growth and survival. A recent study demonstrated that type III strains are cleared from naive murine bone marrow-derived macrophages (BMDMs) via NADPH oxidase 2 (NOX2) (27). Additionally, it is known that mitochondrially derived ROS (mROS) are capable of aiding in the clearance of bacteria (46,47). To test whether NOX2-derived ROS or mROS played a role in parasite restriction, we infected confluent monolayers of HFFs pretreated with either GSK2795039, a NOX2specific inhibitor (48), or Necrox-5, an mROS scavenger (47), with IIIDrop16 parasites and assayed growth, survival, and ROS generation. Treatment of HFFs with either GSK2795039 or Necrox-5 was sufficient to restore growth and survival of IIIDrop16 parasites to WT III levels ( Fig. 6A and B). Additionally, treatment of HFFs with either GSK2795039 or Necrox-5 was sufficient to lower host cell ROS accumulation during IIIDrop16 infection to WT III levels (Fig. 6C). Taken together, these results indicate that both NOX2-derived ROS and mROS play a role in restriction of IIIDrop16 parasites.

DISCUSSION
The data presented here show that one well-studied polymorphic effector protein, ROP16, is responsible for suppressing IFN-g-independent production of ROS, allowing for efficient parasite growth and survival of an avirulent type III strain of T. gondii in HFFs. We have shown that efficient survival of the type III strain during its lytic life cycle in HFFs requires a ROP16 that has a functional kinase domain and can activate STATs. We also observed that ROP16-mediated suppression of ROS occurred in other host backgrounds (mouse) and other cell types (macrophages). Using a combination of cytokine stimulation and HFF STAT knockdown or mETF STAT6KO cell lines, we deter- mined that ROP16-dependent activation of STAT6 is required to abrogate ROS-mediated restriction of type III parasite growth and survival. Finally, using pharmacological inhibitors we showed that both NOX2 and mitochondria are sources of ROS that restrict type III parasites in the absence of ROP16 III . These findings highlight a role for ROS as an IFN-g-independent mechanism of parasite control that is suppressed by ROP16 III in human cells.
Though we have identified a previously unrecognized role for ROP16 in repression of host cell ROS production, we have not identified what host-parasite interactions trigger the production of ROS that is ultimately suppressed by ROP16 III . Interestingly, we observed that uninfected cells in these cultures showed a trend toward an increased accumulation of ROS compared to uninfected cells in cultures with WT III parasites. Given that we have previously shown that T. gondii injects its rhoptry contents into cells it does not invade (26), these data may indicate that injection of ROP proteins without ROP16 triggers the host cell ROS response. Another possibility is that the actively infected cells release a signal that has a paracrine effect that produces ROS in neighboring uninfected cells.
While we have not determined what host-parasite interactions trigger the production of ROS, we have identified both NOX2 and mitochondria as important sources of ROS generation. NADPH oxidases are known to drive the respiratory burst that kills ROP16 Activation of STAT6 Suppresses ROS Production ® phagocytosed pathogens (49). Though we have not performed electron microscopy studies to show the exact mechanism by which the ROS kill parasites, we anticipate that such studies would be consistent with the transmission electron microscopy studies done in a recent paper that implicated NADPH oxidase in the control of intracellular type III parasites in naive murine macrophages (27). The NADPH oxidase-dependent effect in this prior study identified a ROP16-independent effect, highlighting that ROS killing mechanisms may differ between immune cells (macrophages) and non-immune cells (fibroblasts) and between hosts (murine versus human).
Our observation that mROS also played a role in parasite restriction is in keeping with several studies that have shown that mROS plays an important role in macrophage killing of phagosomally localized bacteria (46,47) and extends this work to suggest that mROS may play in important role in pathogen defense in nonimmune cells as well. This finding is especially interesting given that type I and III strains, but not type II strains, show high levels of host mitochondrion association with the PV, the host membrane-derived structure, which surrounds intracellular parasites and avoids fusion with the phagolysosome (50)(51)(52)(53)(54)(55)(56)(57)(58)(59). Host mitochondria associating with the PV might be able to deliver mitochondrion-derived vesicles harboring ROS (47) to the underlying parasites. Such a mechanism might also partially explain why strains that have host mitochondrial association also retain a ROP16 that can suppress ROS production. Additionally, at least one study has shown that STAT6 colocalizes with mitochondria (60) and thus may have other roles outside of acting as a transcription factor. Future studies will focus on the link between type I and III strains' host cell mitochondrion association and STAT6-dependent suppression of host ROS generation.
While invasion of its host cell and establishment of the PV during T. gondii infection are processes that are largely conserved between strains, a growing body of research has shown that the repertoire of secreted effector proteins can have distinct functions between strains such as the activation of STATs by type I and III alleles of ROP16 and NF-κB activation by GRA15 in type II strains (20,(61)(62)(63)(64). Notably, type II strains lack a ROP16 that can activate STATs, though it is predicted to have a functional kinase domain (20)(21)(22)(23)(24). This difference raises the question of how type II strains avoid ROS-mediated parasite restriction. A few possible explanations include that type II strains might not trigger an ROS response, or they might have a compensatory ROP16-independent mechanism that suppresses ROS production or an increased capacity for tolerating the presence of ROS. Interestingly, type II strains that lack ROP16 show no in vivo defect and may even cause an increase in CNS parasite burden (65). Together, these data highlight that host-specific pressures likely influenced the evolution of T. gondii strainspecific traits. Type III strains may have evolved to survive in hosts with particularly strong ROS responses. Future work should be directed toward determining what downstream STAT6-regulated genes are involved in blocking ROS production and identifying how differences in ROS production in T. gondii's broad host range affect the survival of different T. gondii strains.

MATERIALS AND METHODS
Parasite maintenance. As previously described, all parasite strains used in this study were maintained through serial passage in human foreskin fibroblasts (gift of John Boothroyd, Stanford University, Stanford, CA) using Dulbecco modified Eagle medium (DMEM), supplemented with 10% fetal bovine serum, 2 mM glutagro, and 100 IU/ml penicillin and 100 mg/ml streptomycin (cDMEM). In addition to the strains described below, the previously described type III (CEP), IIIDrop16, and ROP16 III strains expressing mCherry or tdTomato were also used (25).
IC-21 and THP1 cell lines. IC-21s (gift of Janko Nikolich-Zugich, University of Arizona) were maintained in RPMI 1640 1 L-glutamine supplemented with 10% fetal bovine serum, and 100 IU/ml penicillin and 100 mg/ml streptomycin prior to downstream experiments. THP1s (gift of Felicia Goodrum, University of Arizona) were maintained in RPMI 1640 1 L-glutamine supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, and 100 IU/ml penicillin and 100 mg/ml streptomycin prior to downstream experiments. THP1 monocyte-macrophage differentiation was induced as previously described prior to downstream experiments (39). Briefly, THP1s were added to glass coverslips on 24-well plates and treated with 100 nM 12-O-tetra-decanoylphorbol-13-acetate (TPA) for 24 h and then replaced with standard growth medium for 48 h, after which the differentiated macrophages were used in downstream experiments.
Generation of plasmids containing ROP16 constructs. All the primers used to make and validate the IIIDrop16 strain are listed in Table S1 in the supplemental material. The ROP16 construct-expressing plasmids were constructed using a previously described FLAG-tagged ROP16-encoding vector and the In-Fusion mutagenesis kit and protocol (Takara, no. 638920) (25).
Generation of ROP16 mutant strains. Generation of IIIDrop16 and ROP16 III parasites was previously described (25). For the newly generated strains, IIIDrop16 parasites were transfected with 50 mg of linearized plasmid DNA harboring FLAG-tagged ROP16 constructs and a bleomycin resistance marker. Selection for bleomycin resistance was performed as previously described (25,66). Post-transfection freshly egressed parasites were resuspended in DMEM supplemented with 50 mg/ml of Zeocin (InvivoGen, 11006-33-0) for 4 h and then added to HFF monolayers supplemented with 5 mg/ml Zeocin to select for integrants. This process was repeated 3 times prior to plating by limiting dilution to isolate single clones. Single clones were subsequently screened by PCR for ROP16 integration (Fig. S1A; PCR primers listed in Table S1).
Plaque assay. Confluent monolayers of HFF cells were infected with 200 tachyzoites of the indicated strains in cDMEM, and cultures were left undisturbed for 10 days to allow for development of plaques, after which the media in the cultures was aspirated, and the cultures were fixed in ice-cold 100% methanol for 10 min. Fixed monolayers were stained with crystal violet for 15 min at room temperature. Stained monolayers were then analyzed by light microscopy at Â4 magnification for the number of plaques in the HFF monolayers.
T. gondii intracellular growth assays. For the growth assay, parasite growth rate was determined using previously described methods which employ a direct parasite-per-vacuole scoring approach (69). Briefly, freshly syringe-lysed parasites (MOI 1) were added to confluent HFF monolayers grown on glass coverslips and spun down at 300 rpm for 1 min. After 1 h, the cultures were then washed to remove noninvaded parasites. At 24 hpi, infected monolayers were fixed, permeabilized, and stained with anti-SAG1 antibodies (as above) and then analyzed by fluorescence microscopy to identify the number of parasites per vacuole. One hundred vacuoles per coverslip were analyzed. For ROS rescue assays, HFFs were treated with either 5 mM N-acetyl-L-cysteine (Abcam, ab139473), 25 mM GSK2795039 (MedChemExpress, 1415925-18-6), or 10 mM Necrox-5 (Cayman Chemical, no. 17278) at the time of infection for either 6 or 24 hpi. Cells were then fixed, stained, and quantified as above. For cytokine rescue assays, HFFs were treated with 100 ng of recombinant human IL-4 or IL-6 (Sigma-Aldrich numbers I4269 and #I2786) at the time of infection to more closely mimic ROP16 injection. Cells were then fixed, stained, and quantified as above.
T. gondii intracellular survival assays. As previously described, freshly syringe-lysed parasites (MOI 1) were added to confluent HFF monolayers grown on glass coverslips (32). Cells were infected for 6 h followed by 3 PBS washes to remove extracellular parasites. Cells were fixed every 6 hpi up to 24 hpi using 4% formaldehyde. Prior to permeabilization, cells were stained with wheat germ agglutinin (ThermoFisher W11261) conjugated to Alexa Fluor 488 according to manufacturer's recommendations. Cells were then permeabilized and stained with anti-SAG1 antibodies and Alexa Fluor 647-conjugated secondary antibody as described above. Images were acquired at 40Â on a Leica DMI6000 with a motorized stage, using Leica Application Suite X (LAS X). Data from at least 50 fields of view per experiment were used to calculate the percent decrease in infected cells at various time points versus 6 hpi. For ROS rescue assays, HFFs were treated with either 5 mM N-acetyl-L-cysteine (Abcam, ab139473), 25 mM GSK2795039 (MedChemExpress, 1415925-18-6), or 10 mM Necrox-5 (Cayman Chemical, no. 17278) at the time of infection for either 6 or 24 hpi. Cells were then fixed, stained, and quantified as above. For cytokine rescue assays, HFFs were treated with 100 ng of recombinant human IL-4 or IL-6 (Sigma-Aldrich I4269 and I2786) at the time of infection to more closely mimic ROP16 injection. Cells were then fixed, stained, and quantified as above.
Intracellular ROS/RNS measurement assays. Freshly syringe-lysed parasites (MOI 1) were added to confluent HFF monolayers grown on glass coverslips and allowed to infect for 18 h. Cells were then stained using a commercially available cellular ROS/RNS assay kit (Abcam, ab139473) following the manufacturer's protocol. Cells were then imaged at 40Â on a Leica DMI6000 with a motorized stage, using Leica Application Suite X (LAS X). One hundred cells per experiment over 50 fields of view were quantified using ImageJ/FIJI. Briefly, individual cells were selected by using the selection tools and the mean fluorescent intensity per cell was obtained by the measure tool as previously described (70,71).
GBP5 localization assays. HFF monolayers grown on glass coverslips were treated with or without 100 U of IFN-g (R&D Systems, 285-MI-100) for 24 h prior to infection. Cells were then infected for 9 h, after which they were fixed using 4% formaldehyde. Cells were then permeabilized and stained as described above. Images were acquired at 40Â on a Leica DMI6000 with a motorized stage, using Leica Application Suite X (LAS X). Data from at least 50 fields of view per experiment were used to calculate the percent GBP5 localization around the PV.
Generation of murine fibroblasts. B6.129S2(C)-Stat6 tm1Gru /J (STAT6KO) mice were purchased from Jackson Laboratories (stock no. 005977) and bred in the University of Arizona BIO5 Animal Facility in accordance with protocols approved by the University of Arizona Institutional Animal Care and Use Committee. Murine ear tip fibroblasts (mETFs) were generated according to previously described protocols (72). Briefly, 2-mm ear punch biopsy specimens were collected from the pinna of adult mice, submerged in 70% ethanol, and then transferred to mETF culture medium on ice for dissection. Tissue layers were dissected apart, cut into 1-mm by 1-mm pieces, and then transferred to a 6-well gelatin-coated plate containing mETF medium. Tissue pieces were evenly distributed and pressed to the bottom of the wells. Fibroblast outgrowth took approximately 2 weeks to reach confluence, after which mETFs were passaged to 100-mm plates for expansion. mETFs were cultured in DMEM supplemented with 20% fetal bovine serum, 100 IU/ml penicillin, 100 mg/ml streptomycin, 1Â HEPES, and 1Â minimal essential medium with non-essential amino acids. After first passage, culture medium was reduced to 10% fetal bovine serum for line maintenance. To generate WT mETFs, the same procedure was used on ear punch biopsy specimens from C57BL/6 (WT) mice purchased from Jackson Laboratories (stock no. 000664).
Statistical analysis. Graphs were generated and statistical analyses were performed using Prism 8.4.2 software. All experiments were performed at least three independent times, and statistical analyses were conducted on the composite data unless reported otherwise. Unless otherwise specified, the data were analyzed using a one-way analysis of variance (ANOVA) with Dunnett's multiple-comparison test to the control (WT III ). For T. gondii intracellular growth assays, a two-way ANOVA with Dunnett's multiplecomparison test to the control (WT III ) was used.
Data availability. All relevant data are within the paper and its supplemental material. All strains, primers, and plasmids are available upon request.

SUPPLEMENTAL MATERIAL
Supplemental material is available online only.